Zhang Xue-Yan, Cheng Jing, Zhao Ping, Chen Ke-Li, Li Juan
Key Laboratory of Ministry of Education on Traditional Chinese Medicine Resource and Compound Prescription and Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, China.
Evid Based Complement Alternat Med. 2019 Jul 11;2019:7263034. doi: 10.1155/2019/7263034. eCollection 2019.
The prescription (SMP) consists of S. moellendorffii Herba (SM), Smilacis glabrae Rhizoma (SGR), and Plantaginis Semen (PS). It has been commonly used to treat hyperuricemia and acute gouty arthritis as a hospital preparation. This study was aimed at investigating the best compatibility ratio of SMP on hyperuricemia and gouty arthritis and getting better insight of the possible mechanism. , anti-inflammatory activity of SMP was evaluated by lipopolysaccharide (LPS) induced RAW264.7 cells. The release of nitric oxide (NO) was screened by Griess assay, and NF-B p65 and NLRP3 proteins expression was examined by immunofluorescence assay. Then, the levels of creatinine (Cr), blood urea nitrogen (BUN), and uric acid (UA) were detected in mice induced by potassium oxonate, and the paw oedema, inflammatory mediators, and histological examination were analyzed in rats induced by monosodium urate (MSU). HPLC method was employed to investigate the chemical profile of this preparation. SMP-3 (the ratio of SMP:SGR:PS was 3:1:1) exhibited the most potent anti-NO production activity without obvious toxicity. This anti-inflammatory effect was associated with suppression of NF-B p65 nuclear translocation and NLRP3 protein expression. In animal experiments, the levels of BUN and Cr in SMP-3 group were lower than other extract groups, and the level of UA was also remarkably decreased by SMP-3 in hyperuricemic mice (<0.01). Besides, SMP-3 extract was able to prevent the paw edema, reduce gouty joint inflammatory features, and decrease the levels IL-1, PGE-2, IL-8, and NO in gouty arthritis rats. Furthermore, 6-C--D-xylopyranosyl-8-C--D-glucopyranosyl, apigenin, and astilbin were identified from SMP-3 extract.
In summary, SMP-3 may be a potential therapeutic agent for the prevention of hyperuricemic and gout.
该方剂（SMP）由绵萆薢（SM）、土茯苓（SGR）和车前子（PS）组成。它作为医院制剂常用于治疗高尿酸血症和急性痛风性关节炎。本研究旨在探讨SMP治疗高尿酸血症和痛风性关节炎的最佳配伍比例，并深入了解其可能的作用机制。通过脂多糖（LPS）诱导RAW264.7细胞来评估SMP的抗炎活性。采用Griess法检测一氧化氮（NO）的释放，通过免疫荧光法检测NF-κB p65和NLRP3蛋白的表达。然后，检测氧嗪酸钾诱导的小鼠体内肌酐（Cr）、血尿素氮（BUN）和尿酸（UA）水平，并分析尿酸钠（MSU）诱导的大鼠爪部水肿、炎症介质及组织学检查情况。采用高效液相色谱法研究该制剂的化学特征。SMP-3（SMP:SGR:PS比例为3:1:1）表现出最强的抗NO生成活性且无明显毒性。这种抗炎作用与抑制NF-κB p65核转位和NLRP3蛋白表达有关。在动物实验中，SMP-3组的BUN和Cr水平低于其他提取物组，SMP-3还能显著降低高尿酸血症小鼠的UA水平（<0.01）。此外，SMP-3提取物能够预防爪部水肿，减轻痛风性关节炎症特征，并降低痛风性关节炎大鼠体内白细胞介素-1、前列腺素E-2、白细胞介素-8和NO水平。此外，从SMP-3提取物中鉴定出了6-C-α-D-吡喃木糖基-8-C-α-D-吡喃葡萄糖苷、芹菜素和落新妇苷。
综上所述，SMP-3可能是预防高尿酸血症和痛风的潜在治疗药物。
